Total Funding
35
79
Total FundingGrant raised
Growth Score 35 in past quarter
-5 pts
Heat Score 79 in past quarter
15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
21230
AC Immune is a biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials
Andreas Muhs: CSOPast Role: Cardion, Director of Pharmacology & Histology
Marie Kosco-Vilbois: Chief Scientific OfficerPast Role: NovImmune, CSO
About the Company
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications